Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
July 4, 2024
- Over 60% of Generic Firms Carry Jointly Developed Products, 98% of Espha Drugs Fall into This Category
July 3, 2024
- LDP Group Calls for MCI Screening for Early Detection of Alzheimer’s
July 3, 2024
- New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
July 2, 2024
- Sato Named MHLW’s Top Pharmacy Officer; Kiyohara to Steer Drug Pricing Reform
July 2, 2024
- MHLW Shuffles Senior Bureaucrats, Ihara Tapped as Vice Health Minister
July 2, 2024
- PMDA Kicks Off Consultations for Pediatric and Rare Disease Drugs
July 2, 2024
- PMDA Opens 1st Overseas Office in Bangkok
July 2, 2024
- Minister Wants Consensus on Future Generic Industry at Upcoming Confab
July 1, 2024
- MHLW to Revise Process to Share Info on Nitrosamine Impurities after Guidance Issued
June 28, 2024
- MHLW Project Team Proposes New Subsidies for Early R&D of Intractable Disease Drugs
June 28, 2024
- MHLW Sets Up Global Strategy HQ to Bolster Innovation Ecosystem
June 28, 2024
- MHLW Panel OKs Different Safety Scheme for Fujimoto’s Revlimid Generic despite Concerns
June 27, 2024
- Constitutional Democratic Party Calls for Scrapping Off-Year Price Revisions
June 27, 2024
- Sakigake Tag to Be Withdrawn for Lisata’s Cell Therapy CLBS12
June 27, 2024
- Health Minister Set to Meet Generic Execs to Hear Views on Industry Revamp
June 26, 2024
- Japan's First Eylea Biosimilar Wins Nod, Potential Listing in November
June 25, 2024
- Health Ministry Changes Avigan Approval Conditions
June 25, 2024
- Japan Approves Novartis’ Fabhalta, Lilly’s Jaypirca, and Lots More
June 25, 2024
- Japan OKs Honebuto Paper, Modest Wording on Off-Year Revisions Finalized
June 24, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…